| 1 |
Lai KN. Pathogenesis of IgA nephropathy[J]. Nat Rev Nephrol, 2012, 8(5)：275-283.
|
| 2 |
Sofue T, Suzuki H, Ueda N, et al. Post-transplant immunoglobulin A deposition and nephropathy in allografts[J]. Nephrology (Carlton), 2018, 23(Suppl 2)：4-9.
|
| 3 |
Wyld ML, Chadban SJ. Recurrent IgA nephropathy after kidney transplantation[J]. Transplantation, 2016, 100(9)：1827-1832.
|
| 4 |
Nijim S, Vujjini V, Alasfar S, et al. Recurrent IgA nephropathy after kidney transplantation[J]. Transplant Proc, 2016, 48(8)：2689-2694.
|
| 5 |
Moroni G, Belingheri M, Frontini G, et al. Immunoglobulin A nephropathy. Recurrence after renal transplantation[J]. Front Immunol, 2019, 10：1332.
|
| 6 |
Matsukuma Y, Masutani K, Tsuchimoto A, et al. Effect of steroid pulse therapy on post-transplant immunoglobulin A nephropathy[J]. Nephrology (Carlton), 2018, 23(Suppl 2)：10-16.
|
| 7 |
Lionaki S, Panagiotellis K, Melexopoulou C, et al. The clinical course of IgA nephropathy after kidney transplantation and its management[J]. Transplant Rev (Orlando), 2017, 31(2)：106-114.
|
| 8 |
Cerutti A. The regulation of IgA class switching[J]. Nat Rev Immunol, 2008, 8(6): 421-434.
|
| 9 |
Yeo SC, Cheung CK, Barratt J. New insights into the pathogenesis of IgA nephropathy[J]. Pediatr Nephrol, 2018, 33(5)：763-777.
|
| 10 |
Suzuki H, Kiryluk K, Novak J, et al. The pathophysiology of IgA nephropathy[J]. J Am Soc Nephrol, 2011, 22(10)：1795-1803.
|
| 11 |
Coppo R. Biomarkers and targeted new therapies for IgA nephropathy[J]. Pediatr Nephrol, 2017, 32(5)：725-731.
|
| 12 |
Li W, Peng X, Liu Y, et al. TLR9 and BAFF: their expression in patients with IgA nephropathy[J]. Mol Med Rep, 2014, 10(3): 1469-1474.
|
| 13 |
McCarthy DD, Kujawa J, Wilson C, et al. Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy[J]. J Clin Invest, 2011, 121(10)：3991-4002.
|
| 14 |
Samy E, Wax S, Huard B, et al. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases[J]. Int Rev Immunol, 2017, 36(1)：3-19.
|
| 15 |
Martín-Penagos L, Benito-Hernández A, San Segundo D, et al. A proliferation-inducing ligand increase precedes IgA nephropathy recurrence in kidney transplant recipients[J]. Clin Transplant, 2019, 33(4)：e13502.
|
| 16 |
Sonoda Y, Gohda T, Suzuki Y, et al. Circulating TNF receptors 1 and 2 are associated with the severity of renal interstitial fibrosis in IgA nephropathy[J]. PLoS One, 2015, 10(4): e0122212.
|
| 17 |
Zhang Z, Jiang SM, Ma YP, et al. Expression of the intrarenal angiotensin receptor and the role of renin-angiotensin system inhibitors in IgA nephropathy[J]. Mol Cell Biochem, 2019, 453(1-2): 103-110.
|
| 18 |
Lim WH, Shingde M, Wong G. Recurrent and de novo glomerulonephritis after kidney transplantation[J]. Front Immunol, 2019, 10: 1944.
|
| 19 |
Malhotra PS, Jorna T, Bhandari S. Treatment of immunoglobulin A nephropathy recurrence post-renal transplant[J]. Transplant Proc, 2018, 50(1): 165-167.
|
| 20 |
Courtney AE, McNamee PT, Nelson WE, et al. Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy？[J]. Nephrol Dial Transplant, 2006, 1(12): 3550-3554.
|
| 21 |
Muto M, Manfroi B, Suzuki H, et al. Toll-like receptor 9 stimulation induces aberrant expression of a proliferation-inducing ligand by tonsillar germinal center B cells in IgA nephropathy[J]. J Am Soc Nephrol, 2017, 28(4): 1227-1238.
|
| 22 |
Koshino K, Ushigome H, Sakai K, et al. Outcome of tonsillectomy for recurrent IgA nephropathy after kidney transplantation[J]. Clin Transplant, 2013, 27(Suppl 26): 22-28.
|
| 23 |
Hirano K, Amano H, Kawamura T, et al. Tonsillectomy reduces recurrence of IgA nephropathy in mesangial hypercellularity type categorized by the Oxford classification[J]. Clin Exp Nephrol, 2016, 20(3): 425-432.
|
| 24 |
Katsumata H, Yamamoto I, Komatsuzaki Y, et al. Successful treatment of recurrent immunoglobulin a nephropathy using steroid pulse therapy plus tonsillectomy 10 years after kidney transplantation: a case presentation[J]. BMC Nephrol, 2018, 19(1): 64.
|
| 25 |
Leeaphorn N, Garg N, Khankin EV, et al. Recurrence of IgA nephropathy after kidney transplantation in steroid continuation versus early steroid-withdrawal regimens: a retrospective analysis of the UNOS/OPTN database[J]. Transpl Int, 2018, 31(2): 175-186.
|
| 26 |
Cordeiro Cabral DB, de Sandes-Freitas TV, Medina-Pestana JO, et al. Clinical features, treatment and prognostic factors of post-transplant immunoglobulin A nephropathy[J]. Ann Transplant, 2018, 23：166-175.
|
| 27 |
Zagkotsis G, Vourlakou C, Paraskevopoulos A, et al. Recurrence of crescentic IgA nephropathy after renal transplantation[J]. CEN Case Rep, 2018, 7(2): 268-273.
|
| 28 |
Messina M, di Vico MC, Ariaudo C, et al. Treatment protocol with pulse and oral steroids for IgA nephropathy after kidney transplantation[J]. J Nephrol, 2016, 29(4): 575-583.
|
| 29 |
Berthoux F, El Deeb S, Mariat C, et al. Antithymocyte globulin (ATG) induction therapy and disease recurrence in renal transplant recipients with primary IgA nephropathy[J]. Transplantation, 2008, 85(10): 1505-1507.
|
| 30 |
Lee KW, Kim KS, Lee JS, et al. Impact of induction immunosuppression on the recurrence of primary IgA nephropathy[J]. Transplant Proc, 2019, 51(5): 1491-1495.
|
| 31 |
Ziswiler R, Steinmann-Niggli K, Kappeler A, et al. Mycophenolic acid: a new approach to the therapy of experimental mesangial proliferative glomerulonephritis[J]. J Am Soc Nephrol, 1998, 9(11): 2055-2066.
|
| 32 |
Von Visger JR, Gunay Y, Andreoni KA, et al. The risk of recurrent IgA nephropathy in a steroid-free protocol and other modifying immunosuppression[J]. Clin Transplant, 2014, 28(8): 845-854.
|
| 33 |
Tian J, Wang Y, Liu X, et al. Rapamycin ameliorates IgA nephropathy via cell cycle-dependent mechanisms[J]. Exp Biol Med (Maywood), 2015, 240(7): 936-945.
|
| 34 |
Tian J, Wang Y, Zhou X, et al. Rapamycin slows IgA nephropathy progression in the rat[J]. Am J Nephrol, 2014, 39(3): 218-229.
|
| 35 |
Chancharoenthana W, Townamchai N, Leelahavanichkul A, et al. Rituximab for recurrent IgA nephropathy in kidney transplantation: a report of three cases and proposed mechanisms[J]. Nephrology (Carlton), 2017, 22(1): 65-71.
|
| 36 |
Lafayette RA, Canetta PA, Rovin BH, et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction[J]. J Am Soc Nephrol, 2017, 28(4)：1306-1313.
|
| 37 |
Wang Z, Yu C, Zhou LN, et al. Effects of tripterygium wilfordii induction therapy to IgA nephropathy patients with heavy proteinuria[J]. Biol Pharm Bull, 2017, 40(11)：1833-1838.
|
| 38 |
Li H, Kong D, Xu Y, et al. Tripterygium wilfordii inhibits tonsillar IgA production by downregulating IgA class switching in IgA nephropathy[J]. Oncotarget, 2017, 8(65): 109027-109042.
|